Cell therapeutic approaches to immunosuppression after clinical kidney transplantation

doi:10.1007/s00467-017-3599-2

Review

. 2018 Feb;33(2):199-213.

doi: 10.1007/s00467-017-3599-2. Epub 2017 Feb 23.

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation

Affiliations

¹ Division of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany. christian.morath@med.uni-heidelberg.de.
² Department of Internal Medicine V, GMP Core Facility, University of Heidelberg, Heidelberg, Germany.
³ Division of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany.
⁴ Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
⁵ Department of Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
⁶ Department of Radiology, Division of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany.

PMID: 28229281
DOI: 10.1007/s00467-017-3599-2

Review

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation

Christian Morath et al. Pediatr Nephrol. 2018 Feb.

. 2018 Feb;33(2):199-213.

doi: 10.1007/s00467-017-3599-2. Epub 2017 Feb 23.

Authors

Affiliations

¹ Division of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany. christian.morath@med.uni-heidelberg.de.
² Department of Internal Medicine V, GMP Core Facility, University of Heidelberg, Heidelberg, Germany.
³ Division of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120, Heidelberg, Germany.
⁴ Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
⁵ Department of Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
⁶ Department of Radiology, Division of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany.

PMID: 28229281
DOI: 10.1007/s00467-017-3599-2

Abstract

Refinement of immunosuppressive strategies has led to further improvement of kidney graft survival in recent years. Currently, the main limitations to long-term graft survival are life-threatening side effects of immunosuppression and chronic allograft injury, emphasizing the need for innovative immunosuppressive regimens that resolve this therapeutic dilemma. Several cell therapeutic approaches to immunosuppression and donor-specific unresponsiveness have been tested in early phase I and phase II clinical trials in kidney transplantation. The aim of this overview is to summarize current cell therapeutic approaches to immunosuppression in clinical kidney transplantation with a focus on myeloid suppressor cell therapy by mitomycin C-induced cells (MICs). MICs show great promise as a therapeutic agent to achieve the rapid and durable establishment of donor-unresponsiveness in living-donor kidney transplantation. Cell-based therapeutic approaches may eventually revolutionize immunosuppression in kidney transplantation in the near future.

Keywords: Immunosuppression; Mitomycin C-induced cells; Myeloid suppressor cells; Regulatory T cells; Tolerance; Transplantation.

PubMed Disclaimer

Cited by

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.
Morath C, Schmitt A, Schmitt M, Wang L, Kleist C, Opelz G, Süsal C, Tran TH, Scherer S, Schwenger V, Kemmner S, Fischereder M, Stangl M, Hauser IA, Sommerer C, Nusshag C, Kälble F, Speer C, Benning L, Bischofs C, Sauer S, Schubert ML, Kunz A, Hückelhoven-Krauss A, Neuber B, Mehrabi A, Schwab C, Waldherr R, Sander A, Büsch C, Czock D, Böhmig GA, Reiser J, Roers A, Müller-Tidow C, Terness P, Zeier M, Daniel V, Schaier M. Morath C, et al. BMJ Open. 2022 Nov 11;12(11):e066128. doi: 10.1136/bmjopen-2022-066128. BMJ Open. 2022. PMID: 36368749 Free PMC article.
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
Schaier M, Morath C, Wang L, Kleist C, Opelz G, Tran TH, Scherer S, Pham L, Ekpoom N, Süsal C, Ponath G, Kälble F, Speer C, Benning L, Nusshag C, Mahler CF, Pego da Silva L, Sommerer C, Hückelhoven-Krauss A, Czock D, Mehrabi A, Schwab C, Waldherr R, Schnitzler P, Merle U, Schwenger V, Krautter M, Kemmner S, Fischereder M, Stangl M, Hauser IA, Kälsch AI, Krämer BK, Böhmig GA, Müller-Tidow C, Reiser J, Zeier M, Schmitt M, Terness P, Schmitt A, Daniel V. Schaier M, et al. Front Immunol. 2023 Jul 11;14:1089664. doi: 10.3389/fimmu.2023.1089664. eCollection 2023. Front Immunol. 2023. PMID: 37483623 Free PMC article. Clinical Trial.
Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models.
Schneiderman J, Qiu L, Yeap XY, Kang X, Zheng F, Ye J, Xie Y, Wang JJ, Sambandam Y, Mathew J, Li L, Leventhal J, Edelson RL, Zhang ZJ. Schneiderman J, et al. Sci Rep. 2022 May 4;12(1):7298. doi: 10.1038/s41598-022-11290-w. Sci Rep. 2022. PMID: 35508582 Free PMC article.
Phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
Morath C, Schmitt A, Kleist C, Daniel V, Opelz G, Süsal C, Ibrahim E, Kälble F, Speer C, Nusshag C, Pego da Silva L, Sommerer C, Wang L, Ni M, Hückelhoven-Krauss A, Czock D, Merle U, Mehrabi A, Sander A, Hackbusch M, Eckert C, Waldherr R, Schnitzler P, Müller-Tidow C, Hoheisel JD, Mustafa SA, Alhamdani MS, Bauer AS, Reiser J, Zeier M, Schmitt M, Schaier M, Terness P. Morath C, et al. J Clin Invest. 2020 May 1;130(5):2364-2376. doi: 10.1172/JCI133595. J Clin Invest. 2020. PMID: 31990685 Free PMC article. Clinical Trial.

References

1. Nature. 1953 Oct 3;172(4379):603-6 - PubMed
1. J Transl Med. 2015 Aug 21;13:274 - PubMed
1. Stem Cells Transl Med. 2013 Feb;2(2):107-11 - PubMed
1. Transplantation. 2007 Feb 15;83(3):347-50 - PubMed
1. Nat Rev Immunol. 2016 Feb;16(2):90-101 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Nature. 1953 Oct 3;172(4379):603-6 - PubMed

[2] Nature. 1953 Oct 3;172(4379):603-6 - PubMed

[3] J Transl Med. 2015 Aug 21;13:274 - PubMed

[4] J Transl Med. 2015 Aug 21;13:274 - PubMed

[5] Stem Cells Transl Med. 2013 Feb;2(2):107-11 - PubMed

[6] Stem Cells Transl Med. 2013 Feb;2(2):107-11 - PubMed

[7] Transplantation. 2007 Feb 15;83(3):347-50 - PubMed

[8] Transplantation. 2007 Feb 15;83(3):347-50 - PubMed

[9] Nat Rev Immunol. 2016 Feb;16(2):90-101 - PubMed

[10] Nat Rev Immunol. 2016 Feb;16(2):90-101 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation

Affiliations

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical